Intrinsiqs

Is Candel Therapeutics, Inc. overvalued?

Candel Therapeutics, Inc. (CADL) — key valuation metrics and fundamentals.

No verdict
Price
$11.72
Fair value
Current P/E
Normal P/E
Market cap
$858.7M
Dividend yield
0.0%
Return on equity
-60.4%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CADL's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.